Clinical trial • Phase I • Oncology|Haematology
UBX-303061 for B-cell malignancies|Chronic lymphocytic leukaemia|Small lymphocytic lymphoma|Waldenström macroglobulinaemia|B-cell lymphoma
Phase I trial of UBX-303061 for B-cell malignancies|Chronic lymphocytic leukaemia|Small lymphocytic lymphoma|Waldenström macroglobulinaemia|B-cell lymphom…
Overview
- Trial Therapeutic Area
- Oncology|Haematology
- Trial Disease
- B-cell malignancies|Chronic lymphocytic leukaemia|Small lymphocytic lymphoma|Waldenström macroglobulinaemia|B-cell lymphoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 04-09-2024
- First CTIS Authorization Date
- 11-01-2025
Trial design
Phase I trial across 4 sites in Poland.
- Target Sample Size
- 52
Eligibility
Recruits 52 Vulnerable population selected; no details provided on consent or assent processes in the provided record..
- Vulnerable Population
- Vulnerable population selected; no details provided on consent or assent processes in the provided record.
Recruitment
- Planned Sample Size
- 52
- Recruitment Window Months
- 26
- Consent Approach
- No information provided on informed consent or assent in the record; vulnerable population selected but no age-specific consent/assent or languages described.
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 42
Poland
- Earliest CTIS Part Ii Submission Date
- 12-12-2024
- Latest Decision Or Authorization Date
- 25-08-2025
- Processing Time Days
- 256
- Number Of Sites
- 4
- Number Of Participants
- 42
Sites
- Site Name
- Mtz Clinical Research Powered By Pratia
- Department Name
- MTZ Clinical Research Powered By Pratia
- Contact Person Name
- Iwona Hus
- Contact Person Email
- iwona.hus@pratia.com
- Site Name
- Pratia Hematologia Sp. z o.o.
- Department Name
- Pratia Hematologia Sp. z o.o.
- Contact Person Name
- Sebastian Grosicki
- Contact Person Email
- sgrosicki@wp.pl
- Site Name
- Medicover Integrated Clinical Services Sp. z o.o.
- Department Name
- Medicover Integrated Clinical Services Sp. z o.o.
- Contact Person Name
- Dominik Chraniuk
- Contact Person Email
- d.chraniuk@naszlekarz.pl
- Site Name
- Aidport Sp. z o.o.
- Department Name
- Aidport Sp. z o.o.
- Contact Person Name
- Michal Kwiatek
- Contact Person Email
- michal.kwiatek@aidport.pl
Sponsor
Primary sponsor
- Full Name
- Ubix Therapeutics Inc.
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- Korea, Republic of
Investigational products
- Investigational Product Name
- UBX-303061
Related trials
Other published trials that may interest you.
- DAUNORUBICIN HYDROCHLORIDE for Acute myeloid leukemia|Relapsed or refractory acute myeloid leukemia
- Brentuximab vedotin for Peripheral T-cell lymphoma (PTCL) | Anaplastic large cell lymphoma (ALCL) | Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) | Angioimmunoblastic T-cell lymphoma (AITL) | Adult T-cell leukaemia/lymphoma (ATLL) | Enteropathy-associated T-cell lymphoma (EATL) | Hepatosplenic T-cell lymphoma | Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) | Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract | Follicular T-cell lymphoma | Nodal peripheral T-cell lymphoma with T-follicular helper phenotype
- RITUXIMAB for Diffuse large B-cell lymphoma (ABC)
- Lenalidomide for Primary central nervous system lymphoma
- Cytarabine; Daunorubicin for Myelodysplastic syndrome (higher-risk)|Oligoblastic acute myeloid leukaemia (AML)